The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay

Abstract

We read with great interest the study by Price et al. ,1 which verifies that high post-treatment platelet reactivity (HPPR) measured with a point-of-care VerifyNow assay (Accumetrics Inc., San Diego, CA, USA) is associated with post-discharge events after percutaneous coronary intervention (PCI) with drug-eluting stent (DES), including stent thrombosis. To the best of our knowledge, this is the first study to identify a threshold of HPPR of VerifyNow based on the clinical outcomes. Recently, a number of studies have demonstrated that clopidogrel non-responsiveness proven in the laboratory testing, i.e. HPPR, has been associated with an increased risk for cardiovascular events.2 Light transmittance aggregometry …